AFP-464
Tigris Pharmaceuticals, Inc. Sponsored Trials:
A randomized Phase 2 clinical study with AFP-464 is currently enrolling in the US. The primary endpoint of the study is to assess Clinical Benefit Response (CBR= CR + PR + SD = 6 months). The trial is expected to enroll up to 50 patients across the US Oncology Network. The Principal Investigator is Dr. Joanne L. Blume at Texas Oncology-Baylor Charles A. Sammons Cancer Center.
ClinicalTrials.gov:
National Cancer Institute ("NCI") sponsored trials under a Cooperative Research and Development Agreement (CRADA):
Two Phase I studies with AFP-464 are currently enrolling in the United States, sponsored by the National Cancer Institute, at the Mayo Clinic, University of Maryland, and Wayne State University. These studies evaluate AFP-464 in patients with Advanced Solid Tumors. For more information on these trials, please use the link below:
ClinicalTrials.gov:
GGTI-2418
A Phase I study of GGTI-2418 is currently enrolling in the United States. For more information, please contact Tigris Pharmaceuticals at info@tigrispharma.com
GFB-204
Tigris Pharmaceuticals in currently completing preclinical IND enabling studies and is planning to initiate Phase I studies to evaluate GFB-204 as a potential cancer therapeutic in patients with a variety of solid tumors upon IND acceptance.
|
